Pfaller, M.A., Carvalhaes, C., Messer, S.A., et al. (2020) Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). Antimicrobial Agents and Chemotherapy, 64, e00099-20.
https://doi.org/10.1128/AAC.00099-20

has been cited by the following article:

• TITLE: Optimization of Dosage Regimen of Rezafungin against Candida spp. Based on Pharmacokinetic/Pharmacodynamic Analysis

  AUTHORS: Jiuli Hu, Junhui Hu

  KEYWORDS: Invasive Candidiasis, Rezafungin, Pharmacokinetics/Pharmacodynamics, Monte Carlo Simulation

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.11 No.6, June 8, 2020

  ABSTRACT: Invasive candidiasis was the most common nosocomial fungal infection with high morbidity and mortality, which is mainly occurring in immunodeficiency and critical patients. Echinocandins were recommended as first-line drugs for the treatment and prevention of invasive candidiasis. In our study, we aimed to optimize the dosage of Rezafungin against Candida spp. based on pharmacokinetic/pharmacodynamics (PK/PD) analysis. We collected the published data about pharmacokinetic parameters of rezafungin and the MIC distribution of Candida spp. on rezafungin. Monte Carlo simulation was used to calculate probability of target attainment and a cumulative fraction of response to assess the best dosing regimen. The optimal dosage regimen for C. albicans and C. glabrata was 50 mg IV, and the optimal dosage regimen for C. parapsilosis was 100 mg IV. Lastly, rezafungin has an excellent antifungal effect on C. albicans, C. glabrata and C. parapsilosis.